CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

Several forms of inflammation can be distinguished histologically; interestingly, although the disease typically presents with engorgement of scleral vessels, vasculitis is not universally present ...

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company ...

"When I was in the hospital, I heard a lot about all the things I’d probably never be able to do again," says 18-year-old ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

An East Haven High School graduate is beating the odds, providing an inspiring story during this graduation season.  “I’m nervous,” East Haven High School Graduate ...

Direct immunofluorescence (DIF) microscopy showed a 15.5% positivity rate in pediatric patients and changed the clinical ...

The first of the selected abstracts came from Wolfgang Merkt, who presented an update on a patient who originally received third-generation CD19-CAR-T ...

At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON® (budesonide delayed release capsules), the world’s first and only ...